Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00700076 · ClinicalTrials.gov registry record · Phase 1

Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects

A Phase 1 study, sponsored by Yale University.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target

NCT00700076: Completed Phase 1 study, sponsored by Yale University.

NCT00700076 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00700076, a Phase 1 study, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target

Study Summary

Org 25935 is a new putative antipsychotic agent developed by N.V. Organon.The primary objective of this study is to investigate the effect of Org 25935 on ketamine-induced impairments in immediate recall.

Interventions

  • DRUG Ketamine and Org 25935
  • DRUG Placebo and Ketamine

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2008-01-22
Est. Completion 2009-03-09
Phase Phase 1
Yale University

1,492 total trials

What the finished NCT00700076 record still lists

NCT00700076 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 2 interventions - of which Ketamine and Org 25935 is the first listed.

NCT00700076 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00700076 about?

NCT00700076 is a clinical study titled "Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects". Org 25935 is a new putative antipsychotic agent developed by N.V. Organon.The primary objective of this study is to investigate the effect of Org 25935 on ketamine-induced impairments in immediate recall.

What is the current status of trial NCT00700076?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-01-22. Estimated completion is 2009-03-09.

What interventions are being tested in trial NCT00700076?

The interventions under investigation include: Ketamine and Org 25935 (DRUG), Placebo and Ketamine (DRUG).

Who is sponsoring clinical trial NCT00700076?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00700076's enrollment target sits among peer trials

15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00700076, the US trial registry maintained by the National Library of Medicine. NCT00700076 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.